Ocugen (NASDAQ: OCGN) shares were flying high earlier this year. The company signed a deal with India's Bharat Biotech for co-commercialization rights to its coronavirus vaccine candidate in the U.S. The Bharat product was close to market. Since then, Ocugen learned it wouldn't win the right to sell the vaccine in the U.S. as soon as it had hoped.
Investors are nervous about a Food and Drug Administration advisory panel meeting and optimistic about a World Health Organization decision.
Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.